

## Special Issue

# Vaccine Development against Infectious Diseases: State of the Art, New Insights, and Future Directions

### Message from the Guest Editors

COVID-19 vaccines showed the power of immunization to control the pandemic, with a significant reduction in the number of cases in countries that achieved adequate vaccine coverage. Unfortunately, they were also able to expose very clearly the new challenge that the scientific community faces: vaccine hesitancy, included by the WHO in 2019 in the list of "10 Threats to Global Health", along with some infectious diseases such as Ebola, influenza, dengue, and HIV. This research topic aims to aggregate results, reviews, and opinions of researchers in the field of vaccinology against infectious diseases, whether human or veterinary vaccines. Our intention is to disseminate reliable knowledge generated with new and old technologies in the development of vaccines against infectious diseases, in immunopathogenesis and "in vitro" studies, and in experimental models or clinical trials. We are confident that the results obtained in the process of developing vaccines for a given infectious disease, regardless of the stage of development, can help to elucidate questions that are still problematic for others.

### Guest Editors

Dr. Fatima Conceição-Silva

Dr. Paula Mello De Luca

Dr. Josué Lima-Junior

### Deadline for manuscript submissions

closed (20 July 2023)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/132417](https://mdpi.com/si/132417)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).